Adage Capital Partners’s Royalty Pharma RPRX Stock Holding History

Adage Capital Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$140M	Sell	2,500,000 -4,980,633	-67%	-$259M	0.2%	91
2026 Q1	$359M	Sell	7,480,633 -4,259,961	-36%	-$187M	0.55%	23
2025 Q4	$454M	Sell	11,740,594 -225,039	-2%	-$8.58M	0.69%	16
2025 Q3	$422M	Buy	11,965,633 +5,965,633	+99%	+$216M	0.67%	22
2025 Q2	$216M	Sell	6,000,000 -250,000	-4%	-$8.28M	0.36%	43
2025 Q1	$195M	Sell	6,250,000 -10,718,321	-63%	-$340M	0.36%	49
2024 Q4	$433M	Buy	16,968,321 +5,069,127	+43%	+$134M	0.76%	18
2024 Q3	$337M	Buy	11,899,194 +967,263	+9%	+$26.8M	0.59%	23
2024 Q2	$288M	Buy	10,931,931 +115,000	+1%	+$3.19M	0.53%	24
2024 Q1	$329M	Sell	10,816,931 -80,000	-0.7%	-$2.36M	0.62%	24
2023 Q4	$306M	Buy	10,896,931 +1,056,931	+11%	+$29M	0.63%	23
2023 Q3	$267M	Buy	9,840,000 +1,190,000	+14%	+$35.3M	0.61%	24
2023 Q2	$266M	Buy	8,650,000 +1,405,133	+19%	+$47.6M	0.58%	24
2023 Q1	$261M	Buy	7,244,867 +244,867	+3%	+$9.08M	0.59%	24
2022 Q4	$277M	Sell	7,000,000 -1,165,000	-14%	-$48.6M	0.66%	19
2022 Q3	$328M	Sell	8,165,000 -8,542,815	-51%	-$365M	0.81%	12
2022 Q2	$702M	Sell	16,707,815 -8,134,900	-33%	-$333M	1.61%	4
2022 Q1	$968M	Hold	24,842,715	–	–	1.84%	4
2021 Q4	$990M	Buy	24,842,715 +144,900	+0.6%	+$5.63M	1.78%	4
2021 Q3	$893M	Buy	24,697,815 +1,976,000	+9%	+$76.8M	1.76%	4
2021 Q2	$931M	Sell	22,721,815 -1,965,941	-8%	-$83.6M	1.82%	5
2021 Q1	$1.08B	Sell	24,687,756 -14,026,524	-36%	-$665M	2.2%	4
2020 Q4	$1.94B	Sell	38,714,280 -7,301,050	-16%	-$310M	4.22%	2
2020 Q3	$1.94B	Hold	46,015,330	–	–	4.85%	2
2020 Q2	$2.23B	Buy	+46,015,330	New	+$2.28B	5.72%	1

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners's RPRX Position: Q2 2026 in Review

Adage Capital Partners reduced its Royalty Pharma (RPRX) stake by 67% in Q2 2026, selling an estimated $259M and leaving 2,500,000 shares worth $140M. The position accounts for 0.2% of the portfolio, ranked #91.

Adage Capital Partners first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. The position peaked at $2.23B in Q2 2020. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Adage Capital Partners held 2,500,000 shares of Royalty Pharma worth $140M as of Q2 2026.
Adage Capital Partners sold 4,980,633 Royalty Pharma shares in Q2 2026, an estimated $259M.
Royalty Pharma made up 0.2% of Adage Capital Partners's portfolio in Q2 2026, its #91 holding.
Adage Capital Partners first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
Adage Capital Partners's Royalty Pharma position peaked at $2.23B in Q2 2020.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.